| Estimated prevalence of undiagnosed atrial fibrillation in the United States MP Turakhia, J Shafrin, K Bognar, J Trocio, Y Abdulsattar, D Wiederkehr, ... PloS one 13 (4), e0195088, 2018 | 196 | 2018 |
| Economic burden of undiagnosed nonvalvular atrial fibrillation in the United States MP Turakhia, J Shafrin, K Bognar, DP Goldman, PM Mendys, ... The American journal of cardiology 116 (5), 733-739, 2015 | 110 | 2015 |
| The association between observed mobility and quality of life in the near elderly J Shafrin, J Sullivan, DP Goldman, TM Gill PloS one 12 (8), e0182920, 2017 | 98 | 2017 |
| Predicting real-world effectiveness of cancer therapies using overall survival and progression-free survival from clinical trials: empirical evidence for the ASCO value framework DN Lakdawalla, J Shafrin, N Hou, D Peneva, S Vine, J Park, J Zhang, ... Value in Health 20 (7), 866-875, 2017 | 82 | 2017 |
| Utility of cancer value frameworks for patients, payers, and physicians A Chandra, J Shafrin, R Dhawan Jama 315 (19), 2069-2070, 2016 | 79 | 2016 |
| Operating on commission: analyzing how physician financial incentives affect surgery rates J Shafrin Health economics 19 (5), 562-580, 2010 | 76 | 2010 |
| Patterns of adherence to oral atypical antipsychotics among patients diagnosed with schizophrenia JP MacEwan, FM Forma, J Shafrin, A Hatch, DN Lakdawalla, ... Journal of managed care & specialty pharmacy 22 (11), 1349-1361, 2016 | 59 | 2016 |
| Patient versus physician valuation of durable survival gains: implications for value framework assessments J Shafrin, TT Schwartz, T Okoro, JA Romley Value in Health 20 (2), 217-223, 2017 | 43 | 2017 |
| Quality-adjusted cost of care: a meaningful way to measure growth in innovation cost versus the value of health gains D Lakdawalla, J Shafrin, C Lucarelli, S Nicholson, ZM Khan, TJ Philipson Health Affairs 34 (4), 555-561, 2015 | 43 | 2015 |
| Long-term health and economic value of improved mobility among older adults in the United States M Kabiri, M Brauer, J Shafrin, J Sullivan, TM Gill, DP Goldman Value in Health 21 (7), 792-798, 2018 | 30 | 2018 |
| An exploratory case study of the impact of expanding cost-effectiveness analysis for second-line nivolumab for patients with squamous non-small cell lung cancer in Canada: does … J Shafrin, M Skornicki, M Brauer, J Villeneuve, M Lees, N Hertel, ... Health Policy 122 (6), 607-613, 2018 | 27 | 2018 |
| A flexible open-source decision model for value assessment of biologic treatment for rheumatoid arthritis D Incerti, JR Curtis, J Shafrin, DN Lakdawalla, JP Jansen Pharmacoeconomics 37, 829-843, 2019 | 26 | 2019 |
| The economic burden of ACPA-positive status among patients with rheumatoid arthritis J Shafrin, MG Tebeka, K Price, C Patel, K Michaud Journal of Managed Care & Specialty Pharmacy 24 (1), 4-11, 2018 | 24 | 2018 |
| Physician and patient preferences for nonvalvular atrial fibrillation therapies J Shafrin, A Bruno, JP MacEwan, A Campinha-Bacote, J Trocio, M Shah, ... Value in Health 19 (4), 451-459, 2016 | 24 | 2016 |
| Geographic variation in spending, utilization and quality: Medicare and Medicaid beneficiaries T MaCurdy, J Bhattacharya, D Perlroth, J Shafrin, A Au-Yeung, H Bashour, ... accessed on August 25, 2013, 2013 | 24 | 2013 |
| Medication adherence patterns among patients with multiple serious mental and physical illnesses JP MacEwan, AR Silverstein, J Shafrin, DN Lakdawalla, A Hatch, ... Advances in therapy 35, 671-685, 2018 | 22 | 2018 |
| Access to credible information on schizophrenia patients’ medication adherence by prescribers can change their treatment strategies: evidence from an online survey of providers J Shafrin, SG May, A Shrestha, C Ruetsch, N Gerlanc, F Forma, A Hatch, ... Patient preference and adherence, 1071-1081, 2017 | 19 | 2017 |
| Changes in mortality associated with cancer drug approvals in the United States from 2000 to 2016 JP MacEwan, S Dennen, R Kee, F Ali, J Shafrin, K Batt Journal of Medical Economics 23 (12), 1558-1569, 2020 | 18 | 2020 |
| The cost of adherence mismeasurement in serious mental illness: a claims-based analysis J Shafrin, F Forma, E Scherer, A Hatch, E Vytlacil, D Lakdawalla Am J Manag Care 23 (5), e156-e163, 2017 | 18 | 2017 |
| White paper on the value of time savings for patients and healthcare providers of breast cancer therapy: the fixed-dose combination of pertuzumab and trastuzumab for … C Jackisch, F Manevy, S Frank, N Roberts, J Shafrin Advances in Therapy 39 (2), 833-844, 2022 | 17 | 2022 |
Darius N. LakdawallaUniversity of Southern CaliforniaVerified email at healthpolicy.usc.edu